Brief News | Wang Ning, First-Level Researcher of the Shenzhen Science and Technology Innovation Commission, and Delegation Visit Shenzhen Cell Valley to Inspect Construction Progress

Date:02-25  Hits:  Belong to:News

图片.png

On the morning of February 24, 2023, Wang Ning, First-Level Researcher of the Innovation Development Division of the Shenzhen Science and Technology Innovation Commission, and Liao Wen, Director of the Pingshan District Science and Technology Innovation Center, along with their delegation, visited the Shenzhen Cell Valley construction site for inspection and guidance. Shenzhen Cell Valley Chairman Professor Shi Yuanyuan and Chief Scientist Professor Wang Jianxun extended a warm welcome and accompanied the delegation during the inspection.

The delegation carefully listened to reports on the construction scale, investment status, and construction progress of the Shenzhen Cell Valley facility at the Hepalink Industrial Park. Wang Ning stated that the Shenzhen Science and Technology Innovation Commission places great importance on the Shenzhen Cell Valley construction project. As a major public service platform project in Shenzhen, the Commission and relevant departments will provide service guarantees, strengthen communication and liaison with the Shenzhen Cell Valley team, promptly resolve issues encountered during project advancement, and provide further policy assistance and services. Shi Yuanyuan expressed sincere gratitude for the care shown by the municipal and district science and technology innovation leaders and committed to completing the project construction with high quality and high standards, contributing to the development of Shenzhen's cell and gene therapy industry.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@sz-cell.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Cell Valley Group is a leading CGT infrastructure platform in China. We capitalize on the strategic window opened by Decree No. 818 to bridge the gap between clinical research and commercialization.

We pioneer the "Hospital to Industry" (H2I) model. Basically, we act as the core partner for hospitals, providing a one-stop solution for new biomedical tech—covering process development, GMP manufacturing, QC, and commercial rollout. Our mission is to push China's CGT sector from pure R&D into a standardized, scalable industry.